

9



Europäisches Patentamt
European Patent Office
Office européen des brevets

10

Publication number:

0 276 793
A2

12

EUROPEAN PATENT APPLICATION

21

Application number: 88101023.5

22

Date of filing: 25.01.88

51

Int. Cl. A **A61K 31/44**, A61K 31.41,
C07D 249/12, C07D 401.04,
C07D 401.06, C07D 403/04,
C07D 403/06, C07D 409/04,
C07D 409/06, C07D 405/04,
C07D 405/06, C07C159/00,
C07D213/78, C07D333/38

Claims for the following Contracting States: GR
+ ES.

30

Priority: 27.01.87 US 7063
04.12.87 US 126191

43

Date of publication of application:
03.08.88 Bulletin 88/31

64

Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

71

Applicant: MERRELL DOW
PHARMACEUTICALS INC.
2110 E. Galbraith Road
Cincinnati Ohio 45215(US)

72

Inventor: Kane, John M.
6813 Dearwester Drive
Cincinnati Ohio 45236(US)
Inventor: Miller, Francis P.
336 Broadway
Loveland Ohio 45140(US)

74

Representative: Macchetta, Francesco et al
Gruppo Lepetit S.p.A. Patent and Trademark
Department 34, Via Roberto Lepetit
I-21040 Gerenzano (Varese)(IT)

54

3-Aryl-5-alkylthio-4H-1,2,4-triazoles.

57


This invention relates to derivatives of 3-aryl-5-alkylthio-4H-1,2,4-triazoles, to their pharmacological properties and to their use as muscle relaxants, spasmolytics, anticonvulsants and anxiolytics.

EP 0 276 793 A2

3-ARYL-5-ALKYLTHIO-4H-1,2,4-TRIAZOLES

This invention relates to derivatives of 3-aryl-5-alkylthio-4H-1,2,4-triazoles, to the intermediates and processes for their preparation, and to their pharmacological properties and to their use as muscle relaxants, spasmolytics, anticonvulsants and anxiolytics.


More specifically this invention relates to the use of compounds of formula I and their pharmaceutically acceptable salts as muscle relaxants, spasmolytics, anticonvulsants and anxiolytics:



wherein


- Ar is phenyl, naphthyl, or a monocyclic heteroaryl moiety selected from thienyl, pyridyl, pyrrolyl, and N-(C₁₋₆ lower alkyl)pyrrolyl;
 R₁ is C₁₋₆ lower alkyl;
 R₂ is hydrogen or C₁₋₆ lower alkyl;
 R is C₁₋₆ lower alkyl, C₁₋₆ alkoxy, hydroxy, halogeno, or trifluoromethyl and n is zero, 1 or 2, or R_n-(Ar) is methylenedioxyphenyl; and each of m and q is zero, 1 or 2.

Another aspect of this invention relates to novel 5-aryl-3-alkylsulfanyl-4H-1,2,4-triazoles of formula II.



wherein Ar, R₁, R₂, R, m and n have the meanings defined above.

Another aspect of this invention relates to novel 5-aryl-3-alkylsulfonyl-4H-1,2,4-triazoles of formula III,



wherein Ar, R₁, R₂, R, m and n have the meanings defined above, with the proviso that (1) R_n-(Ar)-(CH₂)_m is other than 2-ethoxyphenyl; that (2) when R_n-(Ar)-(CH₂)_m is phenyl and R₁ is methyl, R₂ is C₁₋₆ lower alkyl; and that (3) when R_n-(Ar)-(CH₂)_m represents 4-chlorophenyl, R₂ is other than ethyl.


In Formulas I, II and III, halogeno preferably represents chloro or fluoro, and methyl and ethyl are the preferred lower alkyl moieties, although all the straight and branched manifestations thereof are included. Lower alkoxy radicals include ethers having a alkyl moieties paralleling the C₁₋₆ alkyl group. When "Ar" is phenyl, n is preferably one, representing a mono-substituted phenyl moiety with the R-substituent being a group located at any of the ortho, meta or para positions. When n is 2, the 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-positions are contemplated. Preferably R₁ and R₂ each represents methyl or ethyl.

Representative moieties when "Ar" represents a heterocycle are 2-, 3- or 4-pyridyl, 2- or 3-thienyl, pyrrol-2-yl, and N-alkylpyrrol-3-yl. Preferred is 2-thienyl, with or without an R substituent. State of the art salts of these triazoles may be employed, with the hydrochloride being one of convenience and general applicability. These salts are formed by standard techniques well known in the art.

When "Ar" represents naphthyl the preferred isomer is 2-naphthyl, with the R moiety being attached thereto at any of the available positions, although positions 5-, 6-, 7- or 8- are preferred for either the mono- or di-substituted naphthyl compounds of Formula I.

The thioethers of Formula I may be prepared using processes and procedures analogously known in the art as depicted in Scheme A.


Reaction Scheme A:



wherein R₁, R₂ and R_n-(Ar)-(CH₂)_m are as defined for Formula I, and X is a suitable leaving group.

The sulfoxides and sulfones of Formula I may be prepared by oxidizing the alkylthioethers of Formula Ia with a peracid, preferably m-chloroperoxybenzoic acid (MCPBA), as seen in the following Scheme B.

Reaction Scheme B:



wherein R₁, R₂ and R_n-(Ar)-(CH₂)_m are as defined for Formula I.

The preparation of the R₂-substituted thiosemicarbazides (IV) is readily effected by reacting a hydrazine with an isothiocyanate in a suitable solvent. The reaction is quite rapid and may be carried out between 0°C and room temperature. Although the reaction proceeds rapidly, the mixture may be left for up to 24 hours without significant decrease in yield. Reflux conditions may be employed but are not preferred. Almost all solvents may be used. Anhydrous alcohols (preferably ethanol or methanol) are preferred, although

dimethylformamide (DMF), CHCl_3 , CH_2Cl_2 , tetrahydrofuran (THF) and Et_2O may also be used. The required hydrazines and isothiocyanates are readily available but may be prepared by known techniques quite obvious to one of ordinary skill in the art. Once obtained, the thiosemicarbazides are converted to their corresponding aroyl-substituted thiosemicarbazides (VI) by reaction with an appropriate acid chloride (V) in an aprotic solvent such as pyridine, CHCl_3 , THF, and the like. The acylation proceeds rather easily at temperatures ranging from 0°C to room temperature over periods of 3 to 24 hours, although elevated temperatures (e.g., reflux temperatures) may be employed. Again, the acid halides (V) generally are commercially available but may also be prepared from the corresponding acids which are available from obvious starting materials.

The aroyl thiosemicarbazides (VI) are subjected to a cyclization reaction which yields 3-aryl-3H-1,2,4-triazole-5-thiones of formula VII. The cyclization reaction is effected by heating the compounds (VI) in an aqueous base such as sodium bicarbonate or sodium hydroxide. Alcoholic bases may be utilized but generally are less desirable. The reaction is conducted at about the reflux temperature of the solvent, preferably at about $65^\circ\text{--}100^\circ\text{C}$.

The preparation of the alkylthioethers (1a) is readily effected by standard alkylation procedures. Preferably the 3-aryl-3H-1,2,4-triazole-5-thiones (VII) are reacted with the appropriate alkyl halide (R X) or a functional equivalent thereof in the presence of a mild base. Suitable bases are alkali metal carbonates or bicarbonates or alkali metal hydroxides, with K_2CO_3 or aqueous NaOH being preferred. It is preferred to use an alkyl iodide for the alkylation reaction, but any suitable leaving group (e.g., bromide or $-\text{OSO}_2\text{CF}_3$) may be used instead of the iodide. Suitable solvents are acetone, aqueous ethanol, THF, pyridine, and the like. The reaction may be carried out at temperatures ranging from room temperature to the reflux temperature of the reaction mixture, and in general the reaction takes about 15 hours or longer.

The conversion of the 3-aryl-4-alkyl-5-alkylthio-4H-1,2,4-triazoles (1a) to their higher oxidation state is preferably effected by oxidizing the alkylthioethers (1a) with a peracid according to well known conditions. Suitable oxidizing agents are H_2O_2 and NaIO_4 , but m-chloroperoxybenzoic acid is preferred. In effecting the oxidation to the sulfinyl derivatives of formula 1b, 1 molar equivalent of the peracid is used while 2 equivalents of the peracid will yield the sulfonyl derivatives of Formula 1c. The oxidations are carried out at temperatures of about 0°C to room temperature in solvents which themselves are not susceptible to oxidation. Preferred solvents are CH_2Cl_2 , CHCl_3 , acetic acid and ethyl acetate.

Thioethers of Formula 1a have previously been found to be useful as pesticides, bactericides and fungicides, but have not previously been shown to possess muscle relaxant, spasmolytic, anticonvulsant or anxiolytic activity. 3-(4-Chlorophenyl)-4-ethyl-5-methylsulfonyl-4H-1,2,4-triazole was found by M. Y. Mhasalkar, et al. (J. Med. Chem. 14(3), 260-2 (1971)), to have hypoglycemic activity, but neither that compound nor other sulfones of Formula 1c have previously been reported to have muscle relaxant, spasmolytic, anticonvulsant or anxiolytic activity.

It has now been discovered that previously known thioethers and sulfones of Formula I, as well as the novel sulfoxides and sulfones of Formula II and III, exhibit pharmacological effects generally attributed to muscle relaxants, spasmolytics, anti-convulsants and anxiolytics, and thus the compounds of this invention will provide relief in patients suffering from muscle tension, muscle spasms and the pain associated therewith, convulsant seizures and anxiety.

~~Compounds that antagonize the tonic extensor seizures caused by strychnine have been shown to have~~ muscle relaxant, spasmolytic, anticonvulsant and anxiolytic activities in man. The activity of the compounds can be demonstrated by the method of R. A. Turner, Screening Methods in Pharmacology, Chapter 14 (Academic Press, 1965). Groups of 10 to 20 male mice are administered one or more doses of test compound in an appropriate vehicle or, for comparison, the vehicle alone. At a selected time thereafter, strychnine sulfate, prepared as a solution in distilled water, is administered intraperitoneally at a dose of 2.7 mg/kg. Ninety-nine percent of vehicle-treated mice exhibit convulsions at this dose of strychnine. Absence of tonic extension for greater than 15 minutes after strychnine administration is considered significant protection.

Treatment of mice with a dosage range of baclofen, a known anti-spastic muscle relaxant, of from 12.5 to 200 mg/kg i.p. causes over 50% antagonism of strychnine-induced seizures, but no dose causes 100% protection. Tizanidine, a known muscle relaxant, causes maximal protection of 60% at 3.1 mg/kg i.p., but doses of up to 50 mg/kg do not cause a greater effect. Diazepam, a known anxiolytic with muscle relaxant and anticonvulsant activity, causes a dose-related inhibition with an ED_{50} of 1.2 mg/kg i.p.; however very high doses are required for total inhibition of strychnine-induced seizures. In contrast, many of the compounds of the present invention protect 100% against strychnine seizures at doses in the range of 4 times the ED_{50} . Among the compounds of this invention, the intraperitoneally administered ED_{50} is 8.1 mg/kg for 4-methyl-3-phenyl-5-ethylsulfinyl-4H-1,2,4-triazole; 8.5 mg/kg for 4-methyl-3-phenyl-5-ethylsulfonyl-4H-

1,2,4-triazole; 12.8 mg/kg for 4-methyl-3-phenyl-5-methylsulfonyl-4H-1,2,4-triazole; and 18.6 mg/kg for 4-methyl-3-(2-fluorophenyl)-5-ethylthio-4H-1,2,4-triazole.

In their use, the compounds of this invention will exert a relatively quick onset of action and have a prolonged duration of activity. The preferred use is in the treatment of muscle spasms and muscle tension. In general, the compounds will exert their therapeutic effects at dose levels of about 0.25-25 mg/kg of body weight per day although, of course, the degree of severity of the disease state, the age of the patient and other factors determined by the attending diagnostician will influence the exact course and dosage regimen suitable for each patient. In general the parenterally administered dose of the active compounds is about equivalent to that of the orally administered dose.

For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, troches, powders, solutions, suspensions or emulsions. The solid unit dosage forms can be a capsule which can be of the ordinary gelatin type containing, for example, lubricants and inert filler, such as lactose, sucrose or cornstarch. In another embodiment, the compounds of general formula I can be tableted with conventional tablet bases such as lactose, sucrose and cornstarch in combination with binders such as acacia, cornstarch or gelatin, disintegrating agents such as potato starch or alginic acids, and a lubricant such as stearic acid or magnesium stearate.

For parenteral administration, the compounds may be administered as injectable dosages of a solution or suspension of the compound in a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid such as water, alcohols, oils and other acceptable organic solvents, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants. Illustrative of oils which can be employed in these preparations are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil and mineral oil. In general, water, saline, aqueous dextrose and related sugar solutions, ethanol, glycols such as propylene glycol or polyethylene glycol, or 2-pyrrolidone are preferred liquid carriers, particularly for injectable solutions.

The compounds can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or intramuscularly as depot injections or implants. Implants may employ inert material such as biodegradable polymers or synthetic silicones, for example Silastic®, a silicone rubber manufactured by the Dow-Corning Corporation.

As is true in many classes of compounds with a pharmacological activity having a therapeutic end-use application, certain subgeneric groups and certain specific members of the class, because of their overall therapeutic index and their biochemical and pharmacological profile, are preferred. In this instance the preferred compounds of formula I are those wherein R₁ and R₂ groups are methyl or ethyl, those wherein the R substituent is chloro or fluoro, those wherein the R_n substituent is a monochloro or a monofluoro substituent, those wherein n is zero, those wherein m is zero, and those compounds wherein Ar is phenyl. Specifically preferred compounds are:

4-methyl-3-phenyl-5-methylsulfonyl-4H-1,2,4-triazole,
5-ethylsulfinyl-4-methyl-3-phenyl-4H-1,2,4-triazole;
5-ethylsulfonyl-4-methyl-3-phenyl-4H-1,2,4-triazole,
4-methyl-5-methylsulfinyl-3-phenyl-4H-1,2,4-triazole,
5-ethylthio-3-(2-fluorophenyl)-4-methyl-4H-1,2,4-triazole,
3-(2-fluorophenyl)-4-methyl-5-methylsulfonyl-4H-1,2,4-triazole,
3-(2-fluorophenyl)-4-methyl-5-methylthio-4H-1,2,4-triazole,
3-(4-fluorophenyl)-4-methyl-5-methylthio-4H-1,2,4-triazole,
3-(2-chlorophenyl)-4-methyl-5-methylthio-4H-1,2,4-triazole,
4-ethyl-3-(2-fluorophenyl)-5-methylthio-4H-1,2,4-triazole, and
5-ethylthio-4-methyl-3-phenyl-4H-1,2,4-triazole.

The following specific examples are given to illustrate the preparation of the compounds of this invention, although the scope of compound exemplified is not meant to be limiting, this being so in view of the ease by which the compounds of formula I may be prepared. Interchange, or modification, and employment of the necessary intermediates and solvents are quite obvious to a chemist of ordinary skill.

EXAMPLE 1

1-(2-Fluorobenzoyl)-4-methylthiosemicarbazide

To a stirred room temperature suspension of 4-methylthiosemicarbazide (7.9 g, 7.5×10^{-2} mole) and CHCl_3 (190 ml), 2-fluorobenzoyl chloride (9.4 ml, 7.9×10^{-2} mole) was added dropwise. After stirring overnight at room temperature, the precipitate was collected by filtration and the product was washed with two portions of Et_2O . Drying by suction gave a colorless powder: 11.3 g (66%) which was used without further purification in the subsequent cyclization step.

10 Alternate procedure:

To a stirred room temperature solution of 4-methylthiosemicarbazide (10.5 g, 1.00×10^{-1} mole) and pyridine (250 ml), 2-fluorobenzoyl chloride (11.9 ml, 1.00×10^{-1} mole) was added dropwise. After stirring overnight at room temperature the excess pyridine was evaporated at reduced pressure first on a rotary evaporator and then at high vacuum. This afforded a mixture of the desired product and pyridine hydrochloride which is used without further purification in the subsequent cyclization step.

EXAMPLE 21-(4-Pyridoyl)-4-methylthiosemicarbazide

4-Pyridoyl chloride hydrochloride (10.0 g, 5.62×10^{-2} mole) and 4-methylthiosemicarbazide (5.91 g, 5.62×10^{-2} mole) were stirred at room temperature in pyridine (150 ml). After stirring overnight, the pyridine was evaporated at reduced pressure and the concentrate was washed with H_2O . The undissolved product was collected by filtration and dried by suction.

EXAMPLE 31-(2-Thenoyl)-4-methylthiosemicarbazide

A stirred mixture of 2-thiophene carboxylic acid hydrazide (4.75 g, 3.34×10^{-2} mole) and THF (115 ml) was warmed with a heat gun until homogeneous. A solution of freshly distilled methyl isothiocyanate (2.56 g, 3.51×10^{-2} mole) and THF (5 ml) was then added dropwise. After being stirred for about 14 hours the precipitate was collected by filtration, washed with a little Et_2O , and dried by suction affording a colorless powder; 7.1 g (99%).

EXAMPLE 44-Methyl-1-(2-naphthoyl)thiosemicarbazide

To a stirred room temperature solution of 4-methylthiosemicarbazide (5.91 g, 5.62×10^{-2} mole) and pyridine (150 ml) was added 2-naphthoyl chloride (10.7 g, 5.61×10^{-2} mole). After stirring overnight, the pyridine was evaporated at reduced pressure. The concentrate was treated with water and the undissolved product was collected by filtration and dried by suction.

EXAMPLE 55-(2-Fluorophenyl)-2,4-dihydro-4-methyl-3H-1,2,4-triazole-3-thione

1-(2-Fluorobenzoyl)-4-methylthiosemicarbazide (11.3 g, 4.97×10^{-2} mole) or the aforementioned mixture of the above and pyridine hydrochloride and 1 molar aqueous NaHCO_3 (480 ml, 4.80×10^{-1} mole) were stirred and heated to reflux. After refluxing overnight, the reaction was cooled in an ice bath before being

acidified by the dropwise addition of concentrated hydrochloric acid (40 ml, 4.8×10^{-2} mole). The resulting precipitate was collected by filtration, washed with a little H_2O , and dried by suction. This afforded a colorless powder: 5.0 g (48%). This material was of sufficient purity to go on to the next step. If desired this material could be crystallized from EtOAc:hexane affording colorless needles, mp $137-139^\circ C$.

EXAMPLE 6

2,4-Dihydro-4-methyl-5-(4-pyridyl)-3H-1,2,4-triazole-3-thione

1-(4-Pyridoyl)-4-methylthiosemicarbazide (10.4 g, 4.97×10^{-2} mole) and 1 molar aqueous $NaHCO_3$ (480 ml, 4.80×10^{-2} mole) was stirred and heated to reflux. After refluxing overnight, the reaction was cooled in an ice bath before being acidified by the dropwise addition of concentrated hydrochloric acid (40 ml, 4.8×10^{-2} mole). The product was collected by filtration and dried by suction.

EXAMPLE 7

2,4-Dihydro-4-methyl-5-(2-thienyl)-3H-1,2,4-triazole-3-thione

1-(2-Thienoyl)-4-methylthiosemicarbazide (7.1 g, 3.3×10^{-2} mole) and 1 molar aqueous $NaHCO_3$ (330 ml, 3.30×10^{-2} mole) were stirred and heated to reflux. After refluxing about 14 hours the reaction was filtered while hot and the filtrate was then cooled in an ice bath. Acidification by the dropwise addition of concentrated HCl (28 ml, 3.4×10^{-2} mole) gave a colorless precipitate which was collected by filtration, washed with a little cold H_2O , and dried by suction. Crystallization from isopropanol gave colorless spears: 5.0 g (77%), mp $155-157^\circ C$.

EXAMPLE 8

2,4-Dihydro-4-methyl-5-(2-naphthyl)-3H-1,2,4-triazole-3-thione

4-Methyl-1-(2-naphthoyl)thiosemicarbazide (12.9 g, 4.97×10^{-2} mole) and 1 molar aqueous $NaHCO_3$ (480 ml, 4.80×10^{-2} mole) were stirred and warmed to reflux. After refluxing overnight, the reaction was cooled in an ice bath before being acidified by the dropwise addition of concentrated hydrochloric acid (40 ml, 4.8×10^{-2} mole). The resulting product was collected by filtration and dried by suction. Mp $223-225^\circ C$.

EXAMPLE 9

3-(2-Fluorophenyl)-4-methyl-5-methylthio-4H-1,2,4-triazole

A mixture of 5-(2-fluorophenyl)-2,4-dihydro-4-methyl-3H-1,2,4-triazole-3-thione (4.56 g, 2.18×10^{-2} mole), K_2CO_3 (3.01 g, 2.18×10^{-2} mole), methyl iodide (1.5 ml, 2.4×10^{-2} mole), and acetone (65 ml) was stirred and warmed to reflux. After refluxing overnight, the solvent was evaporated and the concentrate was treated with water. The aqueous mixture was extracted three times with EtOAc. The EtOAc extracts were combined, washed with saturated aqueous $NaCl$, and dried over anhydrous Na_2SO_4 . The drying agent was removed by filtration and the filtrate was evaporated at reduced pressure affording a pale yellow oil which was purified by chromatography and kugel rohr distillation, affording a pale yellow oil: 3.55 g (73%), bp = $190-197^\circ C$ (0.3 mm).

EXAMPLE 10

4-methyl-5-methylthio-3-(4-pyridyl)-4H-1,2,4-triazole

A mixture of 2,4-dihydro-4-methyl-5-(4-pyridyl)-3H-1,2,4-triazole-3-thione (4.19 g, 2.18×10^{-2} mole) K_2CO_3 (3.01 g, 2.18×10^{-2} mole), methyl iodide (1.5 ml, 2.4×10^{-2} mole), and acetone (65 ml) was stirred and warmed to reflux. After refluxing overnight, the solvent was evaporated at reduced pressure and the concentrate was treated with water. The aqueous mixture was extracted with EtOAc three times. The EtOAc extracts were combined, washed with saturated aqueous NaCl, and dried over anhydrous Na_2SO_4 . The drying agent was removed by filtration and the filtrate was evaporated at reduced pressure to yield the desired product.

EXAMPLE 113-(2-Thienyl)-4-methyl-5-methylthio-4H-1,2,4-triazole

A solution of methyl iodide (6.3 ml, 1.0×10^{-1} mole) in ethanol (32 ml) was added dropwise to a stirred, room temperature solution of 2,4-dihydro-4-methyl-5-(2-thienyl)-3H-1,2,4-triazole-3-thione (12.5 g, 6.34×10^{-2} mole) and 1 molar aqueous NaOH (142 ml, 1.42×10^{-1} mole). After being stirred for about 14 hours the reaction was extracted four times with EtOAc. The EtOAc extracts were combined, washed with saturated aqueous NaCl, and dried over anhydrous Na_2SO_4 . The drying agent was removed by filtration and the filtrate was evaporated at reduced pressure giving a tacky yellow solid which was purified by flash chromatography (EtOAc). Crystallization from EtOAc gave colorless crystals: 10.5 g (78%), mp 83-85°C.

EXAMPLE 124-Methyl-5-methylthio-3-(2-naphthyl)-4H-1,2,4-triazole

A mixture of 2,4-dihydro-4-methyl-5-(2-naphthyl)-3H-1,2,4-triazole-3-thione (5.26 g, 2.18×10^{-2} mole), K_2CO_3 (3.01 g, 2.18×10^{-2} mole), methyl iodide (1.5 ml, 2.4×10^{-2} mole), and acetone (65 ml) was stirred and warmed to reflux. After refluxing overnight, the solvent was evaporated at reduced pressure and the concentrate was treated with water. The aqueous mixture was extracted with EtOAc three times. The EtOAc extracts were combined, washed with saturated aqueous NaCl, and dried over anhydrous Na_2SO_4 . The drying agent was removed by filtration and the filtrate was evaporated at reduced pressure to yield the desired product. Mp 177-179°C.

EXAMPLE 133-(2-Fluorophenyl)-4-methyl-5-methylsulfinyl-4H-1,2,4-triazole

To a stirred, 0°C, solution of 3-(2-fluorophenyl)-4-methyl-5-methylthio-4H-1,2,4-triazole (5.0 g, 2.2×10^{-2} mole) and CH_2Cl_2 (125 ml) was added portionwise m-chloroperoxybenzoic acid (4.83 g, 2.24×10^{-2} mole, 80% active MCPBA). After stirring overnight at room temperature, the reaction was diluted with CH_2Cl_2 until homogeneous and was then washed in turn twice with saturated aqueous $NaHCO_3$ and once with saturated aqueous NaCl. After drying over anhydrous Na_2SO_4 , the CH_2Cl_2 was evaporated leaving an oil which slowly crystallized. Crystallization from EtOAc-hexane gave a colorless solid: 3.7 g (68%), mp 95-97°C.

EXAMPLE 14

4-Methyl-5-methylsulfinyl-3-(4-pyridyl)-4H-1,2,4-triazole

To a stirred, 0°C. solution of 4-methyl-5-methylthio-3-(4-pyridyl)-4H-1,2,4-triazole (4.54 g, 2.2×10^{-2} mole) and CH_2Cl_2 (125 ml) was added portionwise m-chloroperoxybenzoic acid (4.83 g, 2.24×10^{-2} mole, 80% active MCPBA). After stirring overnight the reaction was diluted with CH_2Cl_2 until homogeneous. The CH_2Cl_2 solution was then washed with saturated aqueous NaHCO_3 and saturated aqueous NaCl . After drying over anhydrous Na_2SO_4 , the CH_2Cl_2 was evaporated at reduced pressure to give the desired product.

10 EXAMPLE 153-(2-Thienyl)-4-methyl-5-methylsulfinyl-4H-1,2,4-triazole

To a stirred, 0°C. solution of 4-methyl-5-methylthio-3-(2-thienyl)-4H-1,2,4-triazole (4.85 g, 2.29×10^{-2} mole) and CH_2Cl_2 (170 ml) was added portionwise m-chloroperoxybenzoic acid (4.95 g, 2.29×10^{-2} mole). After stirring at room temperature overnight the reaction was washed two times with saturated aqueous NaHCO_3 and one time with saturated aqueous NaCl , and dried over anhydrous Na_2SO_4 . The drying agent was removed by filtration and the filtrate was evaporated at reduced pressure yielding an off-white solid which was purified by flash chromatography (40% acetone-EtOAc). Crystallization from EtOAc afforded small colorless plates: 2.78 g (53%), mp 105-107°C.

EXAMPLE 1625 4-Methyl-5-methylsulfinyl-3-(2-naphthyl)-4H-1,2,4-triazole

To a stirred, 0°C. solution of 4-methyl-5-methylthio-3-(2-naphthyl)-4H-1,2,4-triazole (4.00 g, 1.57×10^{-2} mole) and CH_2Cl_2 (110 ml) was added portionwise m-chloroperoxybenzoic acid (3.28 g, 1.57×10^{-2} mole). After stirring overnight at room temperature the reaction was diluted with CH_2Cl_2 (200 ml), washed two times with saturated aqueous NaHCO_3 and one time with saturated aqueous NaCl , and dried over anhydrous Na_2SO_4 . The drying agent was removed by filtration and the filtrate was evaporated at reduced pressure leaving on off-white solid which was purified by flash chromatography (4% $\text{CH}_3\text{OH}:\text{CH}_2\text{Cl}_2$). Crystallization from toluene afforded small colorless plates: 2.5 g (59%), mp 224-226°C.

35 EXAMPLE 173-(2-Fluorophenyl)-4-methyl-5-methylsulfonyl-4H-1,2,4-triazole

To a stirred, 0°C. solution of 3-(2-fluorophenyl)-4-methyl-5-methylthio-4H-1,2,4-triazole (5.0 g, 2.2×10^{-2} mole) and CH_2Cl_2 (125 ml) was added portionwise m-chloroperoxybenzoic acid (12.1 g, 5.6×10^{-2} mole, 80% active MCPBA). After stirring overnight at room temperature, the reaction was diluted with CH_2Cl_2 until homogeneous and was then washed in turn twice with saturated aqueous NaHCO_3 and once with saturated aqueous NaCl . After drying over anhydrous Na_2SO_4 , the CH_2Cl_2 was evaporated at reduced pressure leaving a solid which was purified by chromatography and subsequent crystallization from EtOAc:hexane giving colorless matted needles: 3.6 g (63%) mp 128-130°C.

EXAMPLE 1850 4-Methyl-5-methylsulfonyl-3-(4-pyridyl)-4H-1,2,4-triazole

To a stirred, 0°C. solution of 4-methyl-5-methylthio-3-(4-pyridyl)-4H-1,2,4-triazole (4.54 g, 2.2×10^{-2} mole) and CH_2Cl_2 (125 ml) was added portionwise m-chloroperoxybenzoic acid (9.49 g, 4.4×10^{-2} mole, 80% active MCPBA). The reaction was stirred for 1 hour at 0°C then allowed to warm to room temperature. After stirring overnight, the reaction was diluted with CH_2Cl_2 until homogeneous. The CH_2Cl_2 solution was then washed in turn with saturated aqueous NaHCO_3 and saturated aqueous NaCl . After drying over anhydrous Na_2SO_4 , the CH_2Cl_2 was evaporated at reduced pressure to yield the desired product.

EXAMPLE 193-(2-Thienyl)-4-methyl-5-methylsulfonyl-4H-1,2,4-triazole

- 5 To a stirred, 0°C, solution of 4-methyl-5-methylthio-3-(2-thienyl)-4H-1,2,4-triazole (3.00 g, 1.42×10^{-2} mole) and CH_2Cl_2 (105 ml) was added portionwise m-chloroperoxybenzoic acid 96.42 g, 2.98×10^{-2} mole). After stirring overnight at room temperature, the reaction was washed two times with saturated aqueous NaHCO_3 and one time with saturated NaCl , and dried over anhydrous Na_2SO_4 . The drying agent was removed by filtration and the filtrate was evaporated at reduced pressure, leaving an off-white solid which
10 was purified by flash chromatography (20% $\text{EtOAc}:\text{CH}_2\text{Cl}_2$). Crystallization from $\text{EtOAc}:\text{hexane}$ afforded a colorless solid: 3.5 g (76%), mp 157-159°C.

EXAMPLE 20

15 4-Methyl-5-methylsulfonyl-3-(2-naphthyl)-4H-1,2,4-triazole

- To a stirred, 0°C, solution of 4-methyl-5-methylthio-3-(2-naphthyl)-4H-1,2,4-triazole (5.62 g, 2.20×10^{-2} mole) and CH_2Cl_2 (125 ml) was added portionwise m-chloroperoxybenzoic acid (12.1 g, 5.6×10^{-2} mole, 80% active MCPBA). The reaction was stirred at 0°C for 1 hour and then allowed to warm to room
20 temperature. After stirring overnight, the reaction was diluted with CH_2Cl_2 until homogeneous. The CH_2Cl_2 solution was then washed in turn with saturated aqueous NaHCO_3 and saturated aqueous NaCl . After drying over anhydrous Na_2SO_4 , the CH_2Cl_2 was evaporated at reduced pressure to afford the desired product, which was recrystallized. Mp 204-6°C.

- 25 By substituting the appropriate acid chlorides in the procedure of Example 1 and reacting the resulting thiosemicarbazide according to the procedures of Examples 5, 9, 13 and 17, the tabulated compounds of Formula I are obtained.

30


35

40

45

50


55



Rn-(Ar)-(CH ₂) _m	q	R ₁	R ₂	mp (°C)
phenyl	0	CH ₃	CH ₃	134-136
phenyl	1	CH ₃	CH ₃	144-146
phenyl	2	CH ₃	CH ₃	158-160
phenyl	0	C ₂ H ₅	CH ₃	94-99
phenyl	1	C ₂ H ₅	CH ₃	131-133
phenyl	2	C ₂ H ₅	CH ₃	141-143
4-fluorophenyl	0	CH ₃	H	145-146
4-fluorophenyl	0	CH ₃	CH ₃	193-195
2-fluorophenyl	0	CH ₃	C ₂ H ₅	oil
2-fluorophenyl	0	C ₂ H ₅	CH ₃	95-97
2-fluorophenyl	1	C ₂ H ₅	CH ₃	63-67
2-fluorophenyl	2	C ₂ H ₅	CH ₃	145-147
2-chlorophenyl	0	CH ₃	CH ₃	oil
4-chlorophenyl	0	CH ₃	CH ₃	105-107
4-chlorophenyl	0	CH ₃	C ₂ H ₅	113-115
4-methoxyphenyl	0	CH ₃	CH ₃	149-151
4-methoxyphenyl	1	CH ₃	CH ₃	168-170
4-methoxyphenyl	2	CH ₃	CH ₃	187-189
4-tolyl	0	CH ₃	CH ₃	140-142
4-tolyl	1	CH ₃	CH ₃	161-163
4-tolyl	2	CH ₃	CH ₃	170-172

Claims

1) A compound of the formula



or a pharmaceutically acceptable salts thereof, wherein Ar is phenyl, naphthyl, or a monocyclic heteroaryl moiety selected from thienyl, pyridyl, pyrrolyl, and N-(C₁₋₆ lower alkyl)pyrrolyl;


R₁ is C₁₋₆ alkyl;

R₂ is hydrogen or C₁₋₆ alkyl;

- 5 R is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxyl, halogeno or trifluoromethyl and n is zero, 1 or 2, or R_n-(Ar) is methylenedioxyphenyl; and each of m and q is zero, 1 or 2 for use in the manufacture of a medicament for muscle relaxant, spasmolytic, anticonvulsant or anxiolytic use.

2) A compound of claim 1 for use in the manufacture of a medicament for muscle relaxant, spasmolytic or anticonvulsant use.

- 10 3) A compound of the formula



or a pharmaceutically acceptable salt thereof wherein Ar is phenyl, naphthyl, or a monocyclic heteroaryl moiety selected from thienyl, pyridyl, pyrrolyl, and N-(C₁₋₆ alkyl)pyrrolyl;

R₁ is C₁₋₆ alkyl;

R₂ is hydrogen or C₁₋₆ alkyl;

- 25 R is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, halogeno or trifluoromethyl and n is zero, 1 or 2, or R_n-(Ar) is methylenedioxyphenyl; and each of m and q is zero, 1 or 2, with the proviso that when R_n-Ar-(CH₂)_m represents 4-chlorophenyl and q is zero, R₂ cannot be ethyl and when R_n-Ar-(CH₂)_m represents 4-chlorophenyl, q is 2 and R₂ is ethyl, R₁ cannot be methyl, for use as a medicine.

4) A compound for a use according to claims 1, 2 or 3 wherein Ar is phenyl.

5) A compound for a use according to claim 4 wherein m is zero.

- 6) A compound for use according to claims 1, 2 or 3 wherein n is zero or one, m is zero, R is halogeno, and R₁ and R₂ are independently methyl or ethyl.


7) A compound for a use according to claim 6 wherein q is zero.

8) A compound for a use according to claim 6 wherein q is zero.

9) A compound for a use according to claim 6 wherein q is two.

- 10) A compound for a use according to claims 1, 2 or 3 wherein said compound is selected from
 35 4-methyl-3-phenyl-5-methylsulfonyl-4H-1,2,4-triazole,
 4-methyl-3-phenyl-5-ethylsulfonyl-4H-1,2,4-triazole,
 5-ethylthio-3-(2-fluorophenyl)-4-methyl-4H-1,2,4-triazole,
 3-(2-fluorophenyl)-4-methyl-5-methylsulfonyl-4H-1,2,4-triazole, and
 4-methyl-3-phenyl-5-ethylsulfinyl-4H-1,2,4-triazole.

- 40 11) A compound of the formula



wherein Ar is phenyl, naphthyl, or a heteroaryl moiety selected from thienyl, pyridyl, pyrrolyl, and N-(C₁₋₆ alkyl)pyrrolyl;

R₁ is C₁₋₆ alkyl;

R₂ is hydrogen or C₁₋₆ alkyl;

R is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, halogeno or trifluoromethyl and n is zero, 1 or 2, or R_n-(Ar) is methylenedioxyphenyl; and

- 55 m is zero, 1 or 2;

or a pharmaceutically acceptable salt thereof.

12) A compound of claim 11 wherein Ar is phenyl.


13) A compound of claim 12 wherein m is zero.

14) A compound of claim 11 wherein n is zero or one, m is zero, R is halogeno, and R₁ and R₂ are independently methyl or ethyl.

15) A compound of claim 11 which is 4-methyl-3-phenyl-5-ethylsulfinyl-4H-1,2,4-triazole.

16) A compound of claim 11 which is 3-(2-thienyl)-4-methyl-5-methylsulfinyl-4H-1,2,4-triazole.

17) A compound of the formula



wherein Ar is phenyl, naphthyl, or a heteroaryl moiety selected from thienyl, pyridyl, pyrrolyl, and N-(C₁₋₆alkyl)pyrrolyl;

R₁ is C₁₋₆ alkyl;

R₂ is hydrogen or C₁₋₆ alkyl;


R is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, halogeno or trifluoromethyl and n is zero, 1 or 2, or R_n-(Ar) is methylenedioxyphenyl; and

m is zero, 1 or 2; or a pharmaceutically acceptable salt thereof;

with the provisos that R_n-(Ar)-(CH₂)_m is other than 2-ethoxyphenyl; when R_n-(Ar)-(CH₂)_m represents phenyl and R₁ represents methyl, R₂ is C₁₋₆ alkyl; and when R_n-(Ar)-(CH₂)_m represents 4-chlorophenyl, R₂ is other than ethyl.


18) A pharmaceutical composition containing a compound of claims 3, 11, 12, 13, 14, 15, 16 or 17 in admixture with a pharmaceutically acceptable carrier.

19) A process for preparing a compound of claims 11, 12, 13, 14, 15 or 16 wherein the corresponding thioether of the formula



wherein Ar, R₁, R₂, R, m and n have the meanings defined above, is reacted with about a 1 molar equivalent of a peracidic oxidizing agent at a temperature of from 0°C to room temperature in a solvent which is not susceptible to oxidation.


20) A process for preparing a compound of claim 17 wherein the corresponding thioether of the formula



wherein Ar, R₁, R₂, R, m and n have the meanings defined above, is reacted with about 2 molar equivalents of a peracidic oxidizing agent at a temperature of from 0°C to room temperature in a solvent which is not susceptible to oxidation.

Claims for the following contracting States: ES, GR

1) A compound of the formula



or a pharmaceutically acceptable salts thereof, wherein Ar is phenyl, naphthyl, or a monocyclic heteroaryl moiety selected from thienyl, pyridyl, pyrrolyl, and N-(C₁₋₆ lower alkyl)pyrrolyl;

R₁ is C₁₋₆

15 R₂ is hydrogen or C₁₋₆ alkyl;

R is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxyl, halogeno or trifluoromethyl and n is zero, 1 or 2, or R_n-(Ar) is methylenedioxyphenyl; and each of m and q is zero, 1 or 2 for use in the manufacture of a medicament for muscle relaxant, spasmolytic, anticonvulsant or anxiolytic use.

2) A compound of claim 1 for use in the manufacture of a medicament for muscle relaxant, spasmolytic or anticonvulsant use.

3) A compound for a use according to claims 1 or 2 wherein Ar is phenyl.

4) A compound for a use according to claims 1 or 2 wherein Ar is phenyl and m is zero.

5) A compound for use according to claims 1 or 2 wherein n is zero or one, m is zero, R is halogeno, and R₁ and R₂ are independently methyl or ethyl.

25 6) A compound according to claim 5 wherein q is zero.

7) A compound according to claim 5 wherein q is one.

8) A compound according to claim 5 wherein q is two.

9) A compound for use according to claims 1 or 2 wherein said compound is selected from

4-methyl-3-phenyl-5-methylsulfonyl-4H-1,2,4-triazole,


30 4-methyl-3-phenyl-5-ethylsulfonyl-4H-1,2,4-triazole,

5-ethylthio-3-(2-fluorophenyl)-4-methyl-4H-1,2,4-triazole,

3-(2-fluorophenyl)-4-methyl-5-methylsulfonyl-4H-1,2,4-triazole, and

4-methyl-3-phenyl-5-ethylsulfinyl-4H-1,2,4-triazole.

10) A process for preparation of a compound of the formula




wherein Ar is phenyl, naphthyl, or a heteroaryl moiety selected from thienyl, pyridyl, pyrrolyl, and N-(C₁₋₆ alkyl)pyrrolyl;

45 R₁ is C₁₋₆ alkyl;

R₂ is hydrogen or C₁₋₆ alkyl;

R is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, halogeno or trifluoromethyl and n is zero, 1 or 2, or R_n-(Ar) is methylenedioxyphenyl; and m is zero, 1 or 2,

or a pharmaceutically acceptable salt thereof, wherein the corresponding thioether of the formula



wherein Ar, R₁, R₂, R, m and n have the meanings defined above, is reacted with about a 1 molar equivalent


of a peracidic oxidizing agent at a temperature of from 0°C to room temperature in a solvent which is not susceptible to oxidation.

11) A process according to claim 10 wherein the peracid oxidizing agent is m-chloroperoxybenzoic acid.

12) A process according to claim 10 wherein Ar is phenyl, n is zero or one, m is zero, R is halogeno, and R₁ and R₂ are independently methyl or ethyl.

13) A process according to claim 10 wherein the compound is selected from 4-methyl-3-phenyl-5-ethylsulfinyl-4H-1,2,4-triazole and 3-(2-thienyl)-4-methyl-5-methylsulfinyl-4H-1,2,4-triazole.

14) A process for the preparation of a compound of the formula



wherein Ar is phenyl, naphthyl, or a heteroaryl moiety selected from thienyl, pyridyl, pyrrolyl, and N-(C₁₋₆alkyl)pyrrolyl;


R₁ is C₁₋₆ alkyl;

R₂ is hydrogen or C₁₋₆ alkyl;

R is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, halogeno or trifluoromethyl and n is zero, 1 or 2, or R_n-(Ar) - is methylenedioxyphenyl; and m is zero, 1 or 2; or a pharmaceutically acceptable salt thereof;

with the proviso that R_n-(Ar)-(CH₂)_m is other than 2-ethoxyphenyl; when R_n-(Ar)-(CH₂)_m represents phenyl and R₁ represents methyl, R₂ is C₁₋₆ alkyl; and when R_n-(Ar)-(CH₂)_m represents 4-chlorophenyl, R₂ is other than ethyl;

wherein the corresponding thioether of the formula



wherein Ar, R₁, R₂, R, m and n have the meanings defined above, is reacted with about a 2 molar equivalents of a peracidic oxidizing agent at a temperature of from 0°C to room temperature in a solvent which is not susceptible to oxidation.

15) A process according to claim 14 wherein the peracid oxidizing agent is m-chloroperbenzoic acid.

16) A process according to claim 14 wherein n is zero or one, m is one, R is halogeno and R₁ and R₂ are independently methyl or ethyl.

17) A process according to claim 14 wherein the compound is selected from 4-methyl-3-phenyl-5-methylsulfonyl-4H-1,2,4-triazole; 3-(2-fluorophenyl)-4-methyl-5-methylsulfonyl-4H-1,2,4-triazole; 4-methyl-3-phenyl-5-ethylsulfonyl-4H-1,2,4-triazole; and 3-(2-thienyl)-4-methyl-5-methylsulfonyl-4H-1,2,4-triazole.

EUROPEAN PATENT APPLICATION

Application number: 88101023.5

Date of filing: 25.01.88

Int. Cl.⁴: A 61 K 31/44

A 61 K 31/41, C 07 D 249/12,
 C 07 D 401/04,
 C 07 D 401/06,
 C 07 D 403/04,
 C 07 D 403/06,
 C 07 D 409/04,
 C 07 D 409/06,
 C 07 D 405/04, C 07 D 405/06
 // C07C159/00, C07D213/78,
 C07D333/38

Priority: 27.01.87 US 7063 04.12.87 US 126191

Date of publication of application:
03.08.88 Bulletin 88/31

Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

Date of deferred publication of search report:
21.09.88 Bulletin 88/38

Applicant: MERRELL DOW PHARMACEUTICALS INC.
2110 East Galbraith Road
Cincinnati Ohio 45215-6300 (US)


Inventor: Kane, John M.
6813 Dearwester Drive
Cincinnati Ohio 45236 (US)

Miller, Francis P.
336 Broadway
Loveland Ohio 45140 (US)

Representative: Macchetta, Francesco et al
Gruppo Lepetit S.p.A. Patent and Trademark Department
34, Via Roberto Lepetit
I-21040 Gerenzano (Varese) (IT)

3-Aryl-5-alkylthio-4H-1,2,4-triazoles.

Compounds of the formula



or a pharmaceutically acceptable salts thereof, wherein Ar is phenyl, naphthyl, or a monocyclic heteroaryl moiety selected from thienyl, pyridyl, pyrrolyl, and N-(C₁₋₆ lower alkyl)pyrrolyl;

R₁ is C₁₋₆ alkyl;

R₂ is hydrogen or C₁₋₆ alkyl;

R is C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, halogeno or trifluoromethyl and n is zero, 1 or 2, or R_n-(Ar) is methylenedioxyphenyl; and each of m and q is zero, 1 or 2 are useful as muscle relaxants, spasmolytics, anticonvulsants and anxiolytics.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 88 10 1023

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL.4)
X	CHEMICAL ABSTRACTS, vol. 74, no. 17, 26th April 1971, page 440, column 1, abstract no. 87989d, Columbus, Ohio, US; & JP - B - 70 34819 (DAINIPPON PHARMACEUTICAL CO., LTD.) 07-11-1970 * abstract * ---	3,17,18 ,20	A 61 K 31/44 A 61 K 31/41 C 07 D 249/12 C 07 D 401/04 C 07 D 401/06 C 07 D 403/04 C 07 D 403/06 C 07 D 409/04 C 07 D 409/06
Y	* abstract * ---	1,2	C 07 D 405/04 C 07 D 405/06 //
X	CHEMICAL ABSTRACTS, vol. 74, no. 17, 26th April 1971, page 440, column 2, abstract no. 87996d, Columbus, Ohio, US; & JP - B - 70 34384 (DAINIPPON PHARMACEUTICAL CO., LTD.) 05-11-1970 * abstract * ---	3,18	C 07 D 405/06 C 07 C 159/00 C 07 D 213/78 C 07 D 333/38
Y	* abstract * ---	1,2	
Y	SCIENTIA PHARMACEUTICA, vol. 46, 1978, pages 298-306; A.A.B. HAZZAA et al.: "Synthesis and biological evaluation of 3-quinolyl-5-mercapto-1,2,4-triazoles" * whole document * ---	1,2	
X	JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 74, 1954, pages 948-951; S. YOSHIDA et al.: "Chemotherapeutics. IV. Cyclizations of 1-isonicotinylthiosemicarbazide", & BEILSTEINS HANDBUCH DER ORGANISCHEN CHEMIE, 4th edition, E 3/4, 1982, 26(3), 2006 --- -/-	17,20	TECHNICAL FIELDS SEARCHED (Int. CL.4) A 61 K 31/00 C 07 D 249/00 C 07 D 401/00 C 07 D 403/00 C 07 D 409/00 C 07 D 405/00
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
BERLIN		15-06-1988	VAN AMSTERDAM L.J.P.
CATEGORY OF CITED DOCUMENTS			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 01.82 (P0401)



European Patent
Office

EUROPEAN SEARCH REPORT

Page 2

Application Number

EP 88 10 1023

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A,D	JOURNAL OF MEDICINAL CHEMISTRY, vol. 14, no. 3, 1971, pages 260-262; M.Y. MHASALKAR et al.: "Further studies in substituted 4H-1,2,4-triazoles for possible hypoglycemic activity" * table II, compounds 10-13, 17-20; page 262 *	3, 17, 18, 20	
A	JOURNAL OF MEDICINAL CHEMISTRY, vol. 9, no. 1, January 1966, pages 42-46; H.L. YALE et al.: "Substituted s-triazoles and related compounds" * table 1, compound 24 *	3	
A	JOURNAL OF MEDICINAL CHEMISTRY, vol. 5, September 1965, pages 676-680; D.H. JONES et al.: "Antiviral chemotherapy. I. The activity of pyridine and quinoline derivatives against neurovaccinia in mice" * table II, compounds 37-40 *	3	
A	BOLLETINO CHIMICO FARMACEUTICO, vol. 108, no. 2, 1969, pages 128-138; F. RUSSO et al.: "Nuovi derivati del 1,2,4-triazolo" * page 129; formulae X, XII *	17	
A	JOURNAL OF THE CHEMICAL SOCIETY, part II, 1949, pages 110-1163; E. HOGGARTH "Compounds related to thiosemicarbazide. Part I. 3-phenyl-1:2:4-triazole derivatives" * page 1163, lines 28-36 *	17	
	--- -/-		TECHNICAL FIELDS SEARCHED (Int. Cl.4)
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 15-06-1988	Examiner VAN AMSTERDAM L.J.P.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03 82 (10/80)



European Patent
Office

EUROPEAN SEARCH REPORT

Page 3

Application Number

EP. 88 10 1023

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
A	RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, vol. 37, no. 3, September 1982, pages 499-502; R.K. JAISWAL et al. "Anticonvulsant activity and monoamine oxidase inhibitory properties of substituted 1,2,4-triazoles" ---		
A	JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 7, 1977, pages 971-975; S.S. PARMAR et al.: "Anticonvulsant activity and selective inhibition of NAD-dependent oxidations in rat brain homogenates by newer mercaptotriazoles" -----		
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 15-06-1988	Examiner VAN AMSTERDAM L.J.P.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (1/9401)